

# Anti-HPV-18 E6phospho

**Catalogue number:** 153965

**Sub-type:** Primary antibody

**Images:**

## Contributor

**Inventor:** Lawrence Banks

**Institute:** International Centre For Genetic Engineering And Biotechnology (ICGEB)

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** Anti-HPV-18 E6phospho

**Alternate name:**

**Class:** Polyclonal

**Conjugate:** Unconjugated

**Description:** Nearly all cases of cervical cancer are associated with HPV infection, with two types, HPV16 and HPV18, present in 70% of cases. A defining feature of cervical cancers and derived cell lines is the continued expression of two viral oncoproteins, E6 and E7. A defining characteristic of E6 oncoproteins derived from cancer-causing HPV types is the presence of a PDZ binding motif (PBM) at the extreme carboxy terminus of the protein which is absent from E6 proteins derived from the so-called low-risk HPV types. Within this PBM is also a protein kinase A (PKA) phospho-acceptor site, which is thought to negatively regulate the association of E6 with its PDZ domain-containing substrates

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:**

**Gender:**

**Isotype:**

**Reactivity:** Human papilloma virus

**Selectivity:**

**Host:** Rabbit

**Immunogen:** Peptide: RQERLQRRRETQV

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:**

**Production details:**

**Formulation:**  
**Recommended controls:**  
**Bacterial resistance:**  
**Selectable markers:**  
**Additional notes:**

## Target details

**Target:** HPV E6

**Target alternate names:**

**Target background:** Nearly all cases of cervical cancer are associated with HPV infection, with two types, HPV16 and HPV18, present in 70% of cases. A defining feature of cervical cancers and derived cell lines is the continued expression of two viral oncoproteins, E6 and E7. A defining characteristic of E6 oncoproteins derived from cancer-causing HPV types is the presence of a PDZ binding motif (PBM) at the extreme carboxy terminus of the protein which is absent from E6 proteins derived from the so-called low-risk HPV types. Within this PBM is also a protein kinase A (PKA) phospho-acceptor site, which is thought to negatively regulate the association of E6 with its PDZ domain-containing substrates

**Molecular weight:**

**Ic50:**

## Applications

**Application:** WB  
**Application notes:**

## Handling

**Format:** Liquid  
**Concentration:**  
**Passage number:**  
**Growth medium:**  
**Temperature:**  
**Atmosphere:**  
**Volume:**  
**Storage medium:**  
**Storage buffer:** Serum  
**Storage conditions:**  
**Shipping conditions:** Shipping at 4° C

## Related tools

**Related tools:**

## References

**References:** Thomas et al. 1999. Mol Cell Biol. 19(2):1092-100. PMID: 9891044. ; Two polymorphic variants of wild-type p53 differ biochemically and biologically. ; Thomas et al. 1996. Oncogene. 13(3):471-80. PMID: 8760288. ; HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence.

CancerTools.org